Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SeikagakuTSE:4548 +0.42%73 EV-to-EBIT is 14.28 as of Aug. 26, 2026, which is 30% above its 10-year median of 10.98. GuruFocus rates TSE:4548 with a GF Score™ of 73/100 and a GF Value™ of 円776.96 (Fairly Valued). The stock has 5 warning signs investors should review. Among 481 Medical Devices & Instruments companies, Seikagaku ranks better than 63.2% on this metric.
The historical rank and industry rank for Seikagaku's EV-to-EBIT or its related term are showing as below:
TSE:4548'
s EV-to-EBIT Range Over the Past 10 Years
Min: -405.86 Med: 10.98 Max: 63.97
Current: 14.28
During the past 13 years, the highest EV-to-EBIT of Seikagaku was 63.97. The lowest was -405.86. And the median was 10.98.
TSE:4548's EV-to-EBIT is ranked better than 63.2% of 481
companies
in the Medical Devices & Instruments industry
Industry Median: 18.93
vs TSE:4548: 14.28
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Seikagaku's Enterprise Value for the quarter that ended in Mar. 2026 was 円25,210 Mil.
Seikagaku's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,759 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seikagaku EV-to-EBIT Related Terms
Seikagaku EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Seikagaku's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Seikagaku's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seikagaku EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Seikagaku's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Seikagaku's EV-to-EBIT falls into.
Seikagaku's current Enterprise Value is 円25,112 Mil.
Seikagaku's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,759 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seikagaku (TSE:4548) has a EV-to-EBIT of 14.28 as of Aug. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Seikagaku and its competitors. This is 30% above median its historical median of 10.98. According to the industry distribution chart, Seikagaku ranks #177 out of 481 companies in the Medical Devices & Instruments industry, placing it in the top 36.8%.
Is Seikagaku's EV-to-EBIT too high?
Seikagaku's current EV-to-EBIT of 14.28 is 30% above median its 10-year median of 10.98. The Medical Devices & Instruments industry median EV-to-EBIT is 18.93. Seikagaku's value of 14.28 is 24.6% below this industry median. Based on the distribution chart, Seikagaku ranks #177 out of 481 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Seikagaku has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Seikagaku's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Seikagaku ranks #177 out of 481 companies for EV-to-EBIT. This puts Seikagaku in the upper half of its industry. The industry median EV-to-EBIT is 18.93. Seikagaku's value of 14.28 is 24.6% below this benchmark. While the company's 10-year median is 10.98 vs. the industry median of 18.93, Seikagaku has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.93, based on 481 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Seikagaku's current EV-to-EBIT of 14.28 is 24.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Seikagaku and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Seikagaku's current EV-to-EBIT is 14.28, which is 30% above median its own 10-year median of 10.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seikagaku stock overvalued right now?
Based on GuruFocus' analysis, Seikagaku (TSE:4548) is currently considered Fairly Valued. The stock's GF Value™ is 円776.96, compared to a current price of 円713.00 — trading 8.2% below its estimated fair value. The current EV-to-EBIT is 14.28, which is 30% above median its 10-year median of 10.98 and 24.6% below the Medical Devices & Instruments industry median of 18.93. Seikagaku's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Seikagaku (TSE:4548), the current EV-to-EBIT is 14.28 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Seikagaku (TSE:4548) Overvalued in 2026?
Based on GuruFocus' analysis, Seikagaku stock appears to be undervalued.
The current stock price of 円713.00 is trading 8.2% below its estimated GF Value™ of 円776.96.
GuruFocus considers Seikagaku to be Fairly Valued.
Key valuation signals for TSE:4548:
EV-to-EBIT: 14.28 (30% above median its 10-year median of 10.98)
GF Value™: 円776.96 vs. price of 円713.00 (8.2% below fair value)
Industry Position: 24.6% below the Medical Devices & Instruments median (#177 of 481)
No single metric tells the full story. See the TSE:4548 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Seikagaku Corp makes and sells pharmaceuticals and medical devices related to glycoconjugates. The firm operates in two segments: pharmaceutical and LAL. The pharmaceutical segment contributes the majority of revenue. This business sells pharmaceutical products made from hyaluronic acid, a major component of glycoconjugates, as well as medical devices and bulk products. The LAL segment manufactures endotoxin-detecting reagents made from limulus amebocyte lysate that are used to control quality in the pharmaceutical manufacturing process. Seikagaku generates the majority of its sales in Japan.
73GF Score
Get the complete analysis for TSE:4548
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4548 has been successfully added to your 
